Amarin Corp Plc (AMRN)

[Whalatane]

So any ideas on how Denner pulls off this big win you're betting on ?

The only way I see him doing it is by loading up on / finding Real World evidence that results like the recent "Vascepa within 12 mths of a CV event " data presented at ACC23 ....are real and reproducible.

Thats a very identifiable population with according to AMRN a NNT ( number needed to treat ) of 11.
That makes this a very cost effective medication for this specific population.

Look at the cost of a revascularisation . In the US it has to be around $20,000. including ER time , Cath lab expense for an Angioplasty at least ...probably a stent .....and assuming they could release patient within 24 hrs

Kiwi